Immunology Is Where Intuition Goes to Die

Which is too bad because we really need to understand how the immune system reacts to the coronavirus.
Which is too bad because we really need to understand how the immune system reacts to the coronavirus.
Researchers caution: It is too soon to say whether pre-existing immune cell memory affects COVID-19 clinical outcomes
LA JOLLA, CA – La Jolla Institute for Immunology (LJI) has announced a $1 million gift from GHR Foundation, an independent global philanthropy based in Minneapolis, MN. This significant gift will support the work of the Coronavirus Immunotherapy Consortium (CoVIC), a global partnership headquartered…
We’re now more than seven months into the coronavirus pandemic that has upended the lives of most of Earth’s inhabitants.
Recovery from the virus seems to stimulate protective immunity, but there’s not enough data to determine how long that protection lasts.
The decline seen in some studies is normal, experts say. But scientists must wait to see whether infection confers long-term protection
COVIC-DB: To co-run the LJI-led CoVIC database in the effort to find ideal therapeutic combinations for the novel coronavirus, the assays that best predict efficacy, and the features that provide protection. Coronavirus Immunotherapy Consortium (CoVIC) CoVIC Database Supported by the…
Reactivity study: A collaboration between the Sette lab and Shane Crotty, Ph.D., to document acquired immunity to SARS-CoV-2 and help guide COVID-19 vaccine developers. Their May 2020 Cell study documents a robust antiviral immune response to SARS-CoV-2 in a group…
A video lecture on Tfh cell biology can be seen here. Germinal centers are the critical sites for the development of long term humoral immunity in the form of antigen-specific memory B lymphocytes and long-lived plasma cells. CD4 T cells…
A small variation has made the novel coronavirus fitter—but not more deadly
International collaboration provides important piece of COVID-19 puzzle
Researchers comb through hundreds of studies to find clues to beating COVID-19
Study finds robust antiviral T cell response in humans with COVID-19 and detects substantial crossreactivity in unexposed individuals; in a piece of good news provides a benchmark for testing of vaccine candidates.
Antibody therapeutics will likely be a critical tool for protecting frontline healthcare workers and those at most risk of SARS-CoV-2 infection
To aid vaccine design, researchers will investigate how a diverse population fights off viral attack
Their analysis provides essential information for vaccine design and the evaluation of diagnostics and vaccine candidates